X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2169) 2169
Publication (220) 220
Book Review (48) 48
Book Chapter (19) 19
Conference Proceeding (5) 5
Magazine Article (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1973) 1973
alemtuzumab (1955) 1955
index medicus (1190) 1190
antibodies, monoclonal - therapeutic use (936) 936
male (931) 931
antibodies, monoclonal, humanized (928) 928
female (896) 896
middle aged (758) 758
antibodies, neoplasm - therapeutic use (741) 741
adult (695) 695
hematology (649) 649
transplantation (623) 623
treatment outcome (561) 561
antineoplastic agents - therapeutic use (523) 523
oncology (489) 489
aged (480) 480
immunosuppressive agents - therapeutic use (471) 471
rituximab (444) 444
antibodies, monoclonal, humanized - therapeutic use (399) 399
immunology (382) 382
therapy (362) 362
leukemia, lymphocytic, chronic, b-cell - drug therapy (358) 358
campath-1h (296) 296
multiple sclerosis (275) 275
monoclonal antibodies (274) 274
surgery (273) 273
antineoplastic combined chemotherapy protocols - therapeutic use (253) 253
antibodies, monoclonal - adverse effects (244) 244
fludarabine (244) 244
animals (229) 229
immunotherapy (226) 226
adolescent (219) 219
antibodies, monoclonal - administration & dosage (217) 217
retrospective studies (211) 211
care and treatment (208) 208
vidarabine - analogs & derivatives (207) 207
antibodies, neoplasm - adverse effects (201) 201
chronic lymphocytic-leukemia (200) 200
cd52 antigen (183) 183
risk factors (181) 181
health aspects (180) 180
follow-up studies (178) 178
immunosuppression (177) 177
stem-cell transplantation (177) 177
transplantation, homologous (176) 176
antibodies, neoplasm - administration & dosage (173) 173
clinical neurology (172) 172
chronic lymphocytic leukemia (170) 170
bone-marrow-transplantation (169) 169
young adult (168) 168
antibodies, monoclonal, murine-derived (165) 165
graft rejection - prevention & control (162) 162
pharmacology & pharmacy (153) 153
leukemia (152) 152
clinical trials as topic (151) 151
cancer (150) 150
research (150) 150
drug therapy (149) 149
recurrence (149) 149
transplantation conditioning - methods (147) 147
stem cells (145) 145
kidney transplantation (141) 141
medicine & public health (141) 141
t cells (141) 141
multiple sclerosis - drug therapy (139) 139
remission induction (137) 137
disease (136) 136
prognosis (133) 133
hematology, oncology and palliative medicine (132) 132
chemotherapy (130) 130
child (130) 130
time factors (128) 128
aged, 80 and over (127) 127
antigens, cd - immunology (123) 123
kidneys (123) 123
survival (122) 122
hematopoietic stem cell transplantation (121) 121
cyclophosphamide (120) 120
graft survival (120) 120
antineoplastic agents - adverse effects (119) 119
recipients (119) 119
versus-host-disease (119) 119
antilymphocyte serum - therapeutic use (118) 118
analysis (117) 117
hematopoietic stem cells (116) 116
antibodies, monoclonal, humanized - administration & dosage (114) 114
graft vs host disease - prevention & control (114) 114
abridged index medicus (113) 113
natalizumab (113) 113
vidarabine - therapeutic use (113) 113
article (110) 110
monoclonal-antibody (110) 110
immunologic factors - therapeutic use (108) 108
disease-free survival (107) 107
survival analysis (107) 107
antineoplastic agents (106) 106
non-hodgkins-lymphoma (106) 106
antibodies, monoclonal, humanized - adverse effects (105) 105
immunosuppressive agents - adverse effects (105) 105
stem cell transplantation (105) 105
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2080) 2080
German (28) 28
French (23) 23
Japanese (14) 14
Spanish (9) 9
Russian (6) 6
Chinese (5) 5
Hungarian (4) 4
Polish (4) 4
Czech (3) 3
Danish (2) 2
Norwegian (2) 2
Bosnian (1) 1
Dutch (1) 1
Finnish (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 11, Issue 12, p. CD010699
Journal Article
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 09/2012, Volume 62, Issue 5, pp. 309 - 335
The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and... 
TUMOR-INFILTRATING LYMPHOCYTES | ANTI-CD40 MONOCLONAL-ANTIBODY | METASTATIC MALIGNANT-MELANOMA | PHASE-II TRIAL | CELL-LUNG-CANCER | PULSED DENDRITIC CELLS | COLONY-STIMULATING FACTOR | ONCOLOGY | HEPATOCELLULAR-CARCINOMA PATIENTS | CHRONIC LYMPHOCYTIC-LEUKEMIA | CD8(+) T-CELLS | Immunotherapy - methods | Dendritic Cells - immunology | Humans | Dendritic Cells - physiology | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Cancer Vaccines - therapeutic use | Neoplasms - therapy | Immunotherapy - trends | Angiogenesis Inhibitors - therapeutic use | Receptor, ErbB-2 - antagonists & inhibitors | Cetuximab | Yttrium Radioisotopes - therapeutic use | Gene Transfer Techniques | Histocompatibility Antigens - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Vaccines, DNA - therapeutic use | alpha-Fetoproteins - therapeutic use | alpha-Fetoproteins - immunology | Neoplasms - immunology | Tumor Necrosis Factor Receptor Superfamily, Member 9 - antagonists & inhibitors | Receptor, Epidermal Growth Factor - antagonists & inhibitors | T-Lymphocytes - immunology | Genetic Vectors | Trastuzumab | Care and treatment | Usage | Research | Health aspects | Immunotherapy | Cancer | Immunology | Cancer therapies | Manipulation | Tumors
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 4, pp. 691 - 715
Abstract Purpose Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their... 
Internal Medicine | Medical Education | cost | disease-modifying treatments | multiple sclerosis | new drugs | pharmacotherapy | cost disease-modifying treatments multiple sclerosis new drugs pharmacotherapy | PEGYLATED INTERFERON BETA-1A | COST-EFFECTIVENESS | ORAL FINGOLIMOD FTY720 | PLACEBO-CONTROLLED PHASE-3 | INTRAMUSCULAR INTERFERON | CLINICAL-EFFICACY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | GLATIRAMER ACETATE | BG-12 DIMETHYL FUMARATE | QUALITY-OF-LIFE | United States | Humans | Immunosuppressive Agents - therapeutic use | Drug Approval | Polyethylene Glycols - economics | Polyethylene Glycols - therapeutic use | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized - economics | Dimethyl Fumarate - economics | Drug Costs - statistics & numerical data | Immunosuppressive Agents - economics | Fingolimod Hydrochloride - therapeutic use | Toluidines - economics | United States Food and Drug Administration | Fingolimod Hydrochloride - economics | Toluidines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Multiple Sclerosis - economics | Alemtuzumab | Interferon-beta - economics | Crotonates - therapeutic use | Crotonates - economics | Dimethyl Fumarate - therapeutic use | Glatiramer Acetate - therapeutic use | Glatiramer Acetate - economics | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Biological response modifiers | Drug approval | Interferon | FDA approval | Drug therapy
Journal Article